Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics, Meir Medical Partner on microRNA Biomarker Study

NEW YORK (GenomeWeb) – Rosetta Genomics announced today that it has partnered with Israel's Meir Medical Center to develop a microRNA-based test to identify non-small cell lung cancer (NSCLC) patients who would benefit from a specific class of immunotherapeutics.

Under the terms of the deal, Rosetta will work with Meir to identify miRNAs that are differentially expressed between PD-L1-positive and PD-L1-negative NSCLC samples. PD-L1 is a protein involved in immune suppression and is overexpressed in certain tumors. A number of drugs have been approved to treat PD-L1 positive cancers including Bristol-Myers Squibb's Opdivo (nivolumab) and Merck's Keytruda (pembrolizumab).

Results of the study will be used to develop a classifier that can differentiate between PD-L1-positive and -negative samples, Rosetta said.

Additional terms of the partnership were not disclosed.

"Identifying the right patients is critical for optimizing the use of this new class of therapeutics, which is transforming the care of patients with cancer who are not responding to other treatment regimens," Maya Gottfried, a Meir researcher and principal investigator of the study, said in a statement. "MicroRNAs, with their high reproducibility, robustness, and accuracy, are well-suited to provide this valuable clinical information."

Rosetta President and CEO Kenneth Berlin added that the study is expected to "build on and support our earlier work with other researchers that suggests microRNAs can be better predictors of response to immuno-oncology drugs than other biomarkers currently being utilized to predict response."

On Monday, the firm announced it was selling its PersonalizeDx business to focus on its miRNA-based thyroid nodule classification test.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.